Prostate-specific antigen screening for prostate cancer: no reduction in Gleason scores.

J. J. Berman, G. W. Moore, E. L. Alonsozana, L. A. Brown

Research output: Contribution to journalArticle

Abstract

Skepticism regarding prostate-specific antigen (PSA) screening arises from the possibility that screening procedures increase the yield of diagnosed prostate cancers occurring in an indolent form that does not require treatment. If PSA screening serves only to increase the yield of clinically trivial prostate cancer, one would expect a drop in the average Gleason score of prostate cancers detected with PSA screening compared with prostate cancers detected before the advent of PSA screening. In a 3-yr study of newly diagnosed prostate cancer, there was almost a 7-fold increase in PSA screening tests ordered between 1989 and 1992 and a greater than 2-fold increase in the number of newly diagnosed prostate cancers. In the same time period, the average Gleason scores of newly diagnosed prostate cancer increased slightly (from 6.2 to 6.5). In this study there was no prognostic difference (as predicted by Gleason score) between prostate cancers in populations whose cancers were diagnosed before and after the increased use of PSA as a screening tool.

Original languageEnglish (US)
Pages (from-to)487-489
Number of pages3
JournalModern Pathology
Volume7
Issue number4
StatePublished - May 1994
Externally publishedYes

Fingerprint

Neoplasm Grading
Prostate-Specific Antigen
Prostatic Neoplasms

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Berman, J. J., Moore, G. W., Alonsozana, E. L., & Brown, L. A. (1994). Prostate-specific antigen screening for prostate cancer: no reduction in Gleason scores. Modern Pathology, 7(4), 487-489.

Prostate-specific antigen screening for prostate cancer : no reduction in Gleason scores. / Berman, J. J.; Moore, G. W.; Alonsozana, E. L.; Brown, L. A.

In: Modern Pathology, Vol. 7, No. 4, 05.1994, p. 487-489.

Research output: Contribution to journalArticle

Berman, JJ, Moore, GW, Alonsozana, EL & Brown, LA 1994, 'Prostate-specific antigen screening for prostate cancer: no reduction in Gleason scores.', Modern Pathology, vol. 7, no. 4, pp. 487-489.
Berman JJ, Moore GW, Alonsozana EL, Brown LA. Prostate-specific antigen screening for prostate cancer: no reduction in Gleason scores. Modern Pathology. 1994 May;7(4):487-489.
Berman, J. J. ; Moore, G. W. ; Alonsozana, E. L. ; Brown, L. A. / Prostate-specific antigen screening for prostate cancer : no reduction in Gleason scores. In: Modern Pathology. 1994 ; Vol. 7, No. 4. pp. 487-489.
@article{d3ec2e59298244faa7d35b7f3153537c,
title = "Prostate-specific antigen screening for prostate cancer: no reduction in Gleason scores.",
abstract = "Skepticism regarding prostate-specific antigen (PSA) screening arises from the possibility that screening procedures increase the yield of diagnosed prostate cancers occurring in an indolent form that does not require treatment. If PSA screening serves only to increase the yield of clinically trivial prostate cancer, one would expect a drop in the average Gleason score of prostate cancers detected with PSA screening compared with prostate cancers detected before the advent of PSA screening. In a 3-yr study of newly diagnosed prostate cancer, there was almost a 7-fold increase in PSA screening tests ordered between 1989 and 1992 and a greater than 2-fold increase in the number of newly diagnosed prostate cancers. In the same time period, the average Gleason scores of newly diagnosed prostate cancer increased slightly (from 6.2 to 6.5). In this study there was no prognostic difference (as predicted by Gleason score) between prostate cancers in populations whose cancers were diagnosed before and after the increased use of PSA as a screening tool.",
author = "Berman, {J. J.} and Moore, {G. W.} and Alonsozana, {E. L.} and Brown, {L. A.}",
year = "1994",
month = "5",
language = "English (US)",
volume = "7",
pages = "487--489",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Prostate-specific antigen screening for prostate cancer

T2 - no reduction in Gleason scores.

AU - Berman, J. J.

AU - Moore, G. W.

AU - Alonsozana, E. L.

AU - Brown, L. A.

PY - 1994/5

Y1 - 1994/5

N2 - Skepticism regarding prostate-specific antigen (PSA) screening arises from the possibility that screening procedures increase the yield of diagnosed prostate cancers occurring in an indolent form that does not require treatment. If PSA screening serves only to increase the yield of clinically trivial prostate cancer, one would expect a drop in the average Gleason score of prostate cancers detected with PSA screening compared with prostate cancers detected before the advent of PSA screening. In a 3-yr study of newly diagnosed prostate cancer, there was almost a 7-fold increase in PSA screening tests ordered between 1989 and 1992 and a greater than 2-fold increase in the number of newly diagnosed prostate cancers. In the same time period, the average Gleason scores of newly diagnosed prostate cancer increased slightly (from 6.2 to 6.5). In this study there was no prognostic difference (as predicted by Gleason score) between prostate cancers in populations whose cancers were diagnosed before and after the increased use of PSA as a screening tool.

AB - Skepticism regarding prostate-specific antigen (PSA) screening arises from the possibility that screening procedures increase the yield of diagnosed prostate cancers occurring in an indolent form that does not require treatment. If PSA screening serves only to increase the yield of clinically trivial prostate cancer, one would expect a drop in the average Gleason score of prostate cancers detected with PSA screening compared with prostate cancers detected before the advent of PSA screening. In a 3-yr study of newly diagnosed prostate cancer, there was almost a 7-fold increase in PSA screening tests ordered between 1989 and 1992 and a greater than 2-fold increase in the number of newly diagnosed prostate cancers. In the same time period, the average Gleason scores of newly diagnosed prostate cancer increased slightly (from 6.2 to 6.5). In this study there was no prognostic difference (as predicted by Gleason score) between prostate cancers in populations whose cancers were diagnosed before and after the increased use of PSA as a screening tool.

UR - http://www.scopus.com/inward/record.url?scp=0028435937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028435937&partnerID=8YFLogxK

M3 - Article

C2 - 7520587

AN - SCOPUS:0028435937

VL - 7

SP - 487

EP - 489

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 4

ER -